Tag Archives: agonist

Glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) potently amplify insulin secretion and influence satiety to reduce food intake1,2,3. Stabilized GLP1R agonists were approved for the treatment of type 2 diabetes in 2008 (ref. 4) and at higher doses for overweight and obesity in 2017 and 2018 (ref. 5). Less attention has been paid to the GIP axis, as multiple …

Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease  Eli Lilly and Company Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity  CNBC Eli Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment  statnews.com Eli Lilly Weight-Loss Drug Mounjaro …